Safety Outcomes in Patients With Ulcerative Colitis Using a Healthcare Administrative Database in the United States
These findings assist in understanding the background risks of safety events in patients with UC and suggest that the incidence of select safety outcomes is comparable between the ELEVATE UC trials and RWD.
Authors
- Chunyang Feng (ORCID: https://orcid.org/0000-0002-8260-7206)
- Milena A. Gianfrancesco (ORCID: https://orcid.org/0000-0002-8351-4626)
- Meenakshi Bewtra (ORCID: https://orcid.org/0000-0002-6489-7043)
- Diogo Branquinho (ORCID: https://orcid.org/0000-0001-8519-6409)
- Marla C. Dubinsky
- Miguel Regueiro
- Aoibhinn McDonnell (ORCID: https://orcid.org/0000-0002-2229-0382)
Institutions
- Cleveland Clinic (US)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- University of Pennsylvania (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1093/ibd/izaf067
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer